{{Distinguish|methoxetamine}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 422235584
| IUPAC_name = 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol
| image = Methoxamine.png
<!--Clinical data-->
| tradename = Vasoxyl 
| Drugs.com = {{drugs.com|international|methoxamine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  Oral
<!--Pharmacokinetic data-->
| protein_bound =  
| elimination_half-life =  3 hours
| excretion =  renal 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 390-28-3
| ATC_prefix = C01
| ATC_suffix = CA10
| PubChem = 6082
| IUPHAR_ligand = 483
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00723
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5857
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = HUQ1KC1YLI
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08201
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 524
<!--Chemical data-->
| C=11 | H=17 | N=1 | O=3
| molecular_weight = 211.258
| smiles = O(c1ccc(OC)cc1C(O)C(N)C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WJAJPNHVVFWKKL-UHFFFAOYSA-N
|drug_name=|alt=|caption=|type=|MedlinePlus=|licence_EU=|licence_US=}}

'''Methoxamine''' is an [[alpha-1 adrenergic receptor|Î±<sub>1</sub>]]-[[adrenergic agonist|adrenergic receptor agonist]],<ref>{{cite book |last1=Pazdernik |first1=Thomas L. |authorlink1= |last2=Kerecsen |first2=Laszlo |editor1-first=Edward F. |editor1-last=Goljan |editor1-link= |others= |title=Pharmacology |trans_title= |url= |format=Paperback |type= |edition=Second |series=Rapid Review |volume= |date= |year=2007 |month= |origyear=2003|publisher=Mosby-Elsevier |location=Philadelphia, PA |isbn=978-0-323-04550-6 |oclc= |doi= |id= |page=39 |pages= |trans_chapter= |chapter=5 |chapterurl= |quote= |ref= |bibcode= |laysummary= |laydate= |separator= |postscript= |lastauthoramp=}}</ref> somewhat similar in structure to [[butaxamine]] and [[2,5-DMA]]. It is no longer marketed.{{Why?|date=July 2017}}.

== See also ==
* [[Sertraline]] 
* [[Phenylephrine]]
* [[Synephrine]]

== References ==
{{Reflist|2}}

{{Stimulants}}
{{Cardiac stimulants excluding cardiac glycosides}}
{{Decongestants}}
{{Adrenergic receptor modulators}}
{{Phenethylamines}}

[[Category:Alpha-adrenergic agonists]]
[[Category:Substituted amphetamines]]
[[Category:Phenol ethers]]


{{cardiovascular-drug-stub}}
{{respiratory-system-drug-stub}}